Nucleai
PrivateLast Round
Series B
Extension
Apr 3, 2024
Total Funding Raised
$58.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nucleai is a biotechnology company that offers a spatial biology software platform designed to enhance precision medicine through advanced artificial intelligence and machine learning technologies.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Drug Discovery, Medical AI, Clinical Trials, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nucleai Comparables
Compare Nucleai with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aignostics | 87% | |
| Panakeia | 84% | |
| Visiopharm | 82% |
Nucleai Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 3, 2024 | ||||
| Series B | Mar 22, 2022 | ||||
| Series A | Jul 7, 2020 | ||||
| Seed | Mar 5, 2018 |
Key People
Founding team and executive leadership
Nucleai Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B Extension, Series B |
| Fosun RZ Capital | Series B Extension, Series B |
| Grove Ventures | Series A, Series B Extension, Series B, Seed |
| M Ventures | Series B Extension |
| Vvc Advisors | Series B |
| Fosun International Capital | Series B |
| Vertex Ventures Israel | Series A, Series B Extension, Series B, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 192% MoM, reaching 5.6K.
- Apr 15, 2026
Integrated spatial proteomics solution for drug development.
Recent news
Latest coverage and updates
- partners_withAug 18, 2026
Nucleai, Inc. partnered with Gilead Sciences, Inc. on Aug 11th '26.
- partners_withJul 16, 2026
Nucleai, Inc. partnered with The University of Glasgow on Jul 16th '26.
Nucleai Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nucleai's valuation, stock price, and market status.
Is Nucleai a public or private company?
Nucleai is a private company.
What is the current stock price of Nucleai?
Nucleai is a private company with no public stock price. No recent secondary market data is available.
How much is Nucleai worth (valuation)?
Valuation information for Nucleai is not publicly available.
Can I buy Nucleai stock?
Nucleai shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Nucleai's last funding round?
Nucleai's most recent funding round was VC Round on April 3, 2024.
Who are the main investors in Nucleai?
Key investors in Nucleai include S32, Grove Ventures, Vertex Ventures Israel, Sanofi Ventures, M Ventures.
Will Nucleai IPO soon?
No public IPO plans have been announced for Nucleai.
How can I track Nucleai secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nucleai's secondary market activity and sign up for updates.